{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:27:27Z","timestamp":1778776047939,"version":"3.51.4"},"reference-count":62,"publisher":"The Fukushima Society of Medical Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2022]]},"DOI":"10.5387\/fms.2021-32","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T22:08:33Z","timestamp":1645567713000},"page":"1-10","source":"Crossref","is-referenced-by-count":11,"title":["Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer"],"prefix":"10.5387","volume":"68","author":[{"given":"Mitsuru","family":"Sugimoto","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayuki","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Konno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Asama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Irie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"},{"name":"Department of Endoscopy, Fukushima Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"},{"name":"Department of Endoscopy, Fukushima Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Takasumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"},{"name":"Department of Endoscopy, Fukushima Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunetaka","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"},{"name":"Department of Endoscopy, Fukushima Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichiro","family":"Kobashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Hikichi","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, Fukushima Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, <b>68<\/b>:394-424, 2018.","DOI":"10.3322\/caac.21492"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, <b>70<\/b>:7-30, 2020.","DOI":"10.3322\/caac.21590"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Afshar N, English DR, Chamberlain JA, <i>et al.<\/i> Differences in cancer survival by remoteness of residence:an analysis of data from a population-based cancer registry. Cancer Causes Control, <b>31<\/b>:617-629, 2020.","DOI":"10.1007\/s10552-020-01303-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol, <b>7<\/b>:163-172, 2010.","DOI":"10.1038\/nrclinonc.2009.236"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Warsame R, Grothey A. Treatment options for advanced pancreatic cancer:a review. Expert Rev Anticancer Ther, <b>12<\/b>:1327-1336, 2012.","DOI":"10.1586\/era.12.115"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fogel EL, Shahda S, Sandrasegaran K, <i>et al.<\/i> A Multidisciplinary Approach to Pancreas Cancer in 2016:A Review. Am J Gastroenterol, <b>112<\/b>:537-554, 2017.","DOI":"10.1038\/ajg.2016.610"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Suker M, Beumer BR, Sadot E, <i>et al.<\/i> FOLFIRINOX for locally advanced pancreatic cancer:a systematic review and patient-level meta-analysis. Lancet Oncol, <b>17<\/b>:801-810, 2016.","DOI":"10.1016\/S1470-2045(16)00172-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Thibodeau S, Voutsadakis IA. FOLFIRINOX chemotherapy in metastatic pancreatic cancer:a systematic review and meta-analysis of retrospective and phase II studies. J Clin Med, <b>7<\/b>:7, 2018.","DOI":"10.3390\/jcm7010007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhang Y, Xu J, Hua J, <i>et al.<\/i> Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer:a systematic review and meta-analysis. J Cancer, <b>10<\/b>:4420-4429, 2019.","DOI":"10.7150\/jca.29898"},{"key":"10","unstructured":"10. Lorgis V, Chauffert B, Gentil J, Ghiringhelli F. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil\/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res, <b>32<\/b>:4125-4130, 2012."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events:a systematic review and meta-analysis. Sci Rep, <b>8<\/b>:8666, 2018.","DOI":"10.1038\/s41598-018-26811-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Loprinzi CL, Reeves BN, Dakhil SR, <i>et al.<\/i> Natural history of paclitaxel-associated acute pain syndrome:prospective cohort study NCCTG N08C1. J Clin Oncol, <b>29<\/b>:1472-1478, 2011.","DOI":"10.1200\/JCO.2010.33.0308"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Reeves BN, Dakhil SR, Sloan JA, <i>et al.<\/i> Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy:North Central Cancer Treatment Group trial N08C1. Cancer, <b>118<\/b>:5171-5178, 2012.","DOI":"10.1002\/cncr.27489"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pachman DR, Qin R, Seisler DK, <i>et al.<\/i> Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol, <b>33<\/b>:3416-3422, 2015.","DOI":"10.1200\/JCO.2014.58.8533"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Loprinzi CL, Lacchetti C, Bleeker J, <i>et al.<\/i> Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:ASCO guideline update. J Clin Oncol, <b>38<\/b>:3325-3348, 2020.","DOI":"10.1200\/JCO.20.01399"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Morfini GA, Burns M, Binder LI, <i>et al.<\/i> Axonal transport defects in neurodegenerative diseases. J Neurosci, <b>29<\/b>:12776-12786, 2009.","DOI":"10.1523\/JNEUROSCI.3463-09.2009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest, <b>101<\/b>:2842-2850, 1998.","DOI":"10.1172\/JCI1130"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis, <b>9<\/b>:220-233, 2002.","DOI":"10.1006\/nbdi.2001.0468"},{"key":"19","unstructured":"19. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of taxol. J Natl Cancer Inst Monogr, 107-115, 1993."},{"key":"20","unstructured":"20. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol, <b>20<\/b>:1-15, 1993."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gogas H, Shapiro F, Aghajanian C, <i>et al.<\/i> The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol, <b>61<\/b>:22-26, 1996.","DOI":"10.1006\/gyno.1996.0090"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Schneider BP, Zhao F, Wang M, <i>et al.<\/i> Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol, <b>30<\/b>: 3051-3057, 2012.","DOI":"10.1200\/JCO.2011.39.8446"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Schneider BP, Li L, Radovich M, <i>et al.<\/i> Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res, <b>21<\/b>:5082-5091, 2015.","DOI":"10.1158\/1078-0432.CCR-15-0586"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.\u3000Breast Cancer Res Treat, <b>159<\/b>: 327-333, 2016.","DOI":"10.1007\/s10549-016-3939-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Smith EM, Beck SL, Cohen J. The total neuropathy score:a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum, <b>35<\/b>:96-102, 2008.","DOI":"10.1188\/08.ONF.96-102"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer, <b>118<\/b>:2250-2260, 2012.","DOI":"10.1002\/cncr.27463"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy:a prospective randomized study. Int J Clin Oncol, <b>15<\/b>:82-87, 2010.","DOI":"10.1007\/s10147-009-0015-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Loprinzi CL, Qin R, Dakhil SR, <i>et al.<\/i> Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol, <b>32<\/b>:997-1005, 2014.","DOI":"10.1200\/JCO.2013.52.0536"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Oki E, Emi Y, Kojima H, <i>et al.<\/i> Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial):a placebo-controlled, double-blind, randomized phase III study.\u3000Int J Clin Oncol, <b>20<\/b>:767-775, 2015.","DOI":"10.1007\/s10147-015-0784-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Smith EM, Pang H, Cirrincione C, <i>et al.<\/i> Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy:a randomized clinical trial.\u3000JAMA, <b>309<\/b>:1359-1367, 2013.","DOI":"10.1001\/jama.2013.2813"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. de Andrade DC, Jacobsen Teixeira M, Galhardoni R, <i>et al.<\/i> Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist, <b>22<\/b>:1154-e1105, 2017.","DOI":"10.1634\/theoncologist.2017-0235"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Avan R, Janbabaei G, Hendouei N, <i>et al.<\/i> The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy:a randomized clinical trial. J Res Med Sci, <b>23<\/b>:52, 2018.","DOI":"10.4103\/jrms.JRMS_1068_17"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy:a randomized controlled trial. Clin Drug Investig, <b>40<\/b>:249-257, 2020.","DOI":"10.1007\/s40261-019-00882-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Rao RD, Michalak JC, Sloan JA, <i>et al.<\/i> Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy:a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer, <b>110<\/b>:2110-2118, 2007.","DOI":"10.1002\/cncr.23008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hirayama Y, Ishitani K, Sato Y, <i>et al.<\/i> Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy:a pilot randomized trial. Int J Clin Oncol, <b>20<\/b>:866-871, 2015.","DOI":"10.1007\/s10147-015-0810-y"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Wang J, Li Q, Xu B, Zhang T, Chen S, Luo Y. Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. Chin J Cancer Res, <b>29<\/b>:411-418, 2017.","DOI":"10.21147\/j.issn.1000-9604.2017.05.05"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hincker A, Frey K, Rao L, <i>et al.<\/i> Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy:a randomized, placebo-controlled, crossover study.\u3000Pain, <b>160<\/b>:1835-1846, 2019.","DOI":"10.1097\/j.pain.0000000000001577"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A, <b>96<\/b>:4154-4157, 1999.","DOI":"10.1073\/pnas.96.7.4154"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Wesselink E, Winkels RM, van Baar H, <i>et al.<\/i> Dietary intake of magnesium or calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Nutrients, <b>10<\/b>:398, 2018.","DOI":"10.3390\/nu10040398"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kaku H, Kumagai S, Onoue H, <i>et al.<\/i> Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel\/carboplatin therapy:A multicenter collaborative study. Exp Ther Med, <b>3<\/b>:60-65, 2012.","DOI":"10.3892\/etm.2011.375"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kono T, Hata T, Morita S, <i>et al.<\/i> Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE):a phase 2, multicenter, randomized, doubleblind, placebocontrolled trial of Goshajinkigan to prevent oxaliplatininduced neuropathy. Cancer Chemother Pharmacol, <b>72<\/b>:1283-1290, 2013.","DOI":"10.1007\/s00280-013-2306-7"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Nishioka M, Shimada M, Kurita N, <i>et al.<\/i> The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol, <b>16<\/b>:322-327, 2011.","DOI":"10.1007\/s10147-010-0183-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol, <b>14<\/b>:2-31, 1997.","DOI":"10.1097\/00004691-199701000-00002"},{"key":"44","unstructured":"44. Hershman DL, Lacchetti C, Dworkin RH, <i>et al.<\/i> Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:American society of clinical oncology clinical practice guideline. J Clin Oncol, <b>32<\/b>:1941-1967, 2014."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer, <b>25<\/b>:195-204, 2017.","DOI":"10.1007\/s00520-016-3404-y"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience, <b>144<\/b>:714-720, 2007.","DOI":"10.1016\/j.neuroscience.2006.09.044"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Gauchan P, Andoh T, Ikeda K, <i>et al.<\/i> Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine:different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull, <b>32<\/b>:732-734, 2009.","DOI":"10.1248\/bpb.32.732"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Peng P, Xi Q, Xia S, <i>et al.<\/i> Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci, <b>32<\/b>:586-590, 2012.","DOI":"10.1007\/s11596-012-1001-y"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Aoki M, Kurauchi Y, Mori A, Nakahara T, Sakamoto K, Ishii K. Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats. Biol Pharm Bull, <b>37<\/b>:322-326, 2014.","DOI":"10.1248\/bpb.b13-00735"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Shinde SS, Seisler D, Soori G, <i>et al.<\/i> Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial. Support Care Cancer, <b>24<\/b>:547-553, 2016.","DOI":"10.1007\/s00520-015-2807-5"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol, <b>121<\/b>:1513-1522, 1997.","DOI":"10.1038\/sj.bjp.0701320"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain, <b>85<\/b>:405-414, 2000.","DOI":"10.1016\/S0304-3959(99)00283-3"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Luo ZD, Chaplan SR, Higuera ES, <i>et al.<\/i> Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci, <b>21<\/b>: 1868-1875, 2001.","DOI":"10.1523\/JNEUROSCI.21-06-01868.2001"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Lynch JJ, 3rd, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain, <b>110<\/b>:56-63, 2004.","DOI":"10.1016\/j.pain.2004.03.010"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain, <b>128<\/b>:225-234, 2007.","DOI":"10.1016\/j.pain.2006.09.016"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Magnowska M, I\u017cycka N, Kapo\u0142a-Czy\u017c J, <i>et al.<\/i> Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.\u3000Ginekol Pol, <b>89<\/b>:200-204, 2018.","DOI":"10.5603\/GP.a2018.0034"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Aghili M, Zare M, Mousavi N, <i>et al.<\/i> Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. Breast J, <b>25<\/b>:226-231, 2019.","DOI":"10.1111\/tbj.13196"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. You MS, Ryu JK, Choi YH, <i>et al.<\/i> Efficacy of Nab-paclitaxel plus gemcitabine and prognostic value of peripheral neuropathy in patients with metastatic pancreatic cancer. Gut Liver, <b>12<\/b>:728-735, 2018.","DOI":"10.5009\/gnl18220"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Catalano M, Aprile G, Ramello M, Conca R, Petrioli R, Roviello G. Association between low-grade chemotherapy-induced peripheral neuropathy (CINP) and survival in patients with metastatic adenocarcinoma of the pancreas. J Clin Med, <b>10<\/b>:1846, 2021.","DOI":"10.3390\/jcm10091846"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Von Hoff DD, Ervin T, Arena FP, <i>et al.<\/i> Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, <b>369<\/b>:1691-1703, 2013.","DOI":"10.1056\/NEJMoa1304369"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain:A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig, <b>10<\/b>:1299-1306, 2019.","DOI":"10.1111\/jdi.13013"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Sugimoto M, Takagi T, Suzuki R, <i>et al.<\/i> Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.\u3000BMC Cancer, <b>21<\/b>:1319, 2021.","DOI":"10.1186\/s12885-021-09069-9"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/68\/1\/68_2021-32\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:56:07Z","timestamp":1715234167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/68\/1\/68_2021-32\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.2021-32","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"2021-32"}}